| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1107663718 |
| P356 | DOI | 10.1038/S41586-018-0623-Z |
| P698 | PubMed publication ID | 33298855 |
| P50 | author | Kankan Wang | Q92285271 |
| P2093 | author name string | Wei Zhang | |
| Ming Zhao | |||
| Xuefei Ma | |||
| Wen Jin | |||
| Shufen Li | |||
| P2860 | cites work | Isolation and purification of bovine immunoglobulins: use of Sephacryl S-300 filtration avoids protein precipitation steps | Q70763124 |
| [On a case of Turner's syndrome] | Q72351193 | ||
| Orally administered THIP inhibits food intake in the rat | Q72928600 | ||
| Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia | Q87226909 | ||
| LncRNA ITGB2-AS1 Could Promote the Migration and Invasion of Breast Cancer Cells through Up-Regulating ITGB2 | Q89242247 | ||
| Functional characterization of long noncoding RNAs | Q89755659 | ||
| Expression of non-coding RNAs in hematological malignancies | Q89951704 | ||
| Long noncoding RNA CRNDE promotes non-small cell lung cancer progression via sponging microRNA-338-3p | Q90560326 | ||
| Genome-wide methods for investigating long noncoding RNAs | Q90808253 | ||
| The Regulatory Roles of Long Noncoding RNAs in Acute Myeloid Leukemia | Q92137481 | ||
| Long non-coding RNA CRNDE enhances cervical cancer progression by suppressing PUMA expression | Q92766921 | ||
| WGCNA: an R package for weighted correlation network analysis | Q21284194 | ||
| SYK is a critical regulator of FLT3 in acute myeloid leukemia | Q24337247 | ||
| Notch1 and Notch2 Inhibit Myeloid Differentiation in Response to Different Cytokines | Q24533662 | ||
| VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing | Q24628978 | ||
| Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 | ||
| High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples | Q24652901 | ||
| Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
| MicroRNA targets in Drosophila | Q24806738 | ||
| Analysis of protein-coding genetic variation in 60,706 humans | Q26831376 | ||
| TopHat-Fusion: an algorithm for discovery of novel fusion transcripts | Q27499675 | ||
| Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation | Q27684364 | ||
| Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies | Q27824769 | ||
| Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia | Q27824808 | ||
| Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations | Q27824843 | ||
| Prognostic relevance of integrated genetic profiling in acute myeloid leukemia | Q27851726 | ||
| An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. | Q27852141 | ||
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
| Genomic Classification and Prognosis in Acute Myeloid Leukemia | Q27853389 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| MicroRNAs modulate hematopoietic lineage differentiation | Q27860661 | ||
| The International HapMap Project | Q27860695 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 | ||
| Acute Myeloid Leukemia | Q28267442 | ||
| ReportingTools: an automated result processing and presentation toolkit for high-throughput genomic analyses | Q45784302 | ||
| The long non-coding RNA CRNDE acts as a ceRNA and promotes glioma malignancy by preventing miR-136-5p-mediated downregulation of Bcl-2 and Wnt2. | Q47116860 | ||
| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study | Q47655563 | ||
| Evidence-Based Precision Oncology with the Cancer Targetome. | Q47893147 | ||
| Long non-coding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. | Q48303376 | ||
| Cytoplasmic functions of long noncoding RNAs | Q51764928 | ||
| microRNA-181a enhances cell proliferation in acute lymphoblastic leukemia by targeting EGR1. | Q52961872 | ||
| Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation | Q53405286 | ||
| Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms | Q54225327 | ||
| A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. | Q54533130 | ||
| RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA. | Q55362553 | ||
| Functional genomic landscape of acute myeloid leukaemia | Q58598813 | ||
| Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias | Q61150129 | ||
| Addressing confounding artifacts in reconstruction of gene co-expression networks | Q64084140 | ||
| Long non-coding RNA CRNDE regulates cell proliferation, migration, invasion, epithelial-mesenchymal transition and apoptosis in oral squamous cell carcinoma | Q64233885 | ||
| Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence | Q28385712 | ||
| Age-related clonal hematopoiesis associated with adverse outcomes | Q28386602 | ||
| Age-related mutations associated with clonal hematopoietic expansion and malignancies | Q28387160 | ||
| Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas | Q28396656 | ||
| Capturing heterogeneity in gene expression studies by surrogate variable analysis | Q28469315 | ||
| The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling | Q29248796 | ||
| Landscape of transcription in human cells | Q29547467 | ||
| Regularization Paths for Generalized Linear Models via Coordinate Descent | Q29614491 | ||
| Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor | Q29614870 | ||
| Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia | Q29615735 | ||
| Comprehensive analysis of kinase inhibitor selectivity | Q29616719 | ||
| Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads | Q29617402 | ||
| limma powers differential expression analyses for RNA-sequencing and microarray studies | Q29617988 | ||
| Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation | Q30455659 | ||
| A high-performance computing toolset for relatedness and principal component analysis of SNP data | Q30573123 | ||
| starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data | Q30705717 | ||
| Eigenanalysis of SNP data with an identity by descent interpretation | Q31008103 | ||
| Complex heatmaps reveal patterns and correlations in multidimensional genomic data. | Q31098875 | ||
| BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia | Q33335885 | ||
| Long noncoding RNA CRNDE activates Wnt/β-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer | Q33623211 | ||
| Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia | Q33702409 | ||
| Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. | Q33716402 | ||
| voom: Precision weights unlock linear model analysis tools for RNA-seq read counts | Q33741687 | ||
| Is my network module preserved and reproducible? | Q33809355 | ||
| PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. | Q34099047 | ||
| Long intergenic non-coding RNA HOTAIRM1 regulates cell cycle progression during myeloid maturation in NB4 human promyelocytic leukemia cells | Q34143034 | ||
| Removing technical variability in RNA-seq data using conditional quantile normalization | Q34143874 | ||
| Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis | Q34301317 | ||
| Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening | Q34307423 | ||
| Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
| The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote | Q34337291 | ||
| Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia | Q34340593 | ||
| featureCounts: an efficient general purpose program for assigning sequence reads to genomic features | Q34384848 | ||
| Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines | Q34441541 | ||
| Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice | Q34441594 | ||
| CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. | Q34487797 | ||
| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite | Q34517403 | ||
| A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy | Q34549807 | ||
| NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth | Q34582832 | ||
| Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome | Q34930673 | ||
| Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells | Q34994576 | ||
| CrossMap: a versatile tool for coordinate conversion between genome assemblies | Q35071536 | ||
| Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics | Q35848830 | ||
| DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. | Q35854312 | ||
| Notch2 Signaling Regulates the Proliferation of Murine Bone Marrow-Derived Mesenchymal Stem/Stromal Cells via c-Myc Expression | Q36195006 | ||
| Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia | Q36515569 | ||
| Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features | Q36606696 | ||
| An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. | Q37125395 | ||
| A landscape of pharmacogenomic interactions in cancer. | Q37140236 | ||
| LncRNA CRNDE promotes hepatic carcinoma cell proliferation, migration and invasion by suppressing miR-384. | Q37382536 | ||
| Notch signaling in acute promyelocytic leukemia | Q37414175 | ||
| TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes | Q37566878 | ||
| Landscape of genetic lesions in 944 patients with myelodysplastic syndromes | Q37571585 | ||
| Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel | Q37624593 | ||
| The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway | Q37633708 | ||
| Acute promyelocytic leukaemia: novel insights into the mechanisms of cure | Q37802188 | ||
| lncRNAs and microRNAs with a role in cancer development | Q38543390 | ||
| Long noncoding RNA CRNDE promotes colorectal cancer cell proliferation via epigenetically silencing DUSP5/CDKN1A expression | Q38630689 | ||
| Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. | Q38636162 | ||
| The Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Progression by Competitively Binding miR-217 with TCF7L2 and Enhancing the Wnt/β-Catenin Signaling Pathway | Q38704831 | ||
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | Q38712298 | ||
| Turning the tide in myelodysplastic/myeloproliferative neoplasms | Q38712988 | ||
| Long noncoding RNA CRNDE stabilized by hnRNPUL2 accelerates cell proliferation and migration in colorectal carcinoma via activating Ras/MAPK signaling pathways | Q38736586 | ||
| CRNDE Promotes Malignant Progression of Glioma by Attenuating miR-384/PIWIL4/STAT3 Axis | Q38779789 | ||
| CRNDE Expression Positively Correlates with EGFR Activation and Modulates Glioma Cell Growth | Q38792627 | ||
| CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling | Q38894596 | ||
| CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. | Q39067728 | ||
| Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group | Q41508288 | ||
| Whole-exome sequencing for finding de novo mutations in sporadic mental retardation | Q42143764 | ||
| A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence | Q42350797 | ||
| Removing batch effects for prediction problems with frozen surrogate variable analysis. | Q42921185 | ||
| A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. | Q44271037 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| functional genomics | Q1068690 | ||
| P304 | page(s) | 121 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Cell Death Discovery | Q27726740 |
| P1476 | title | Functional genomic landscape of acute myeloid leukaemia | |
| P478 | volume | 6 |
| Q94562061 | "Direct to Drug" screening as a precision medicine tool in multiple myeloma |
| Q96127147 | A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study |
| Q98303321 | A compendium of mutational cancer driver genes |
| Q90415585 | Aberrant activation of RPB1 is critical for cell overgrowth in acute myeloid leukemia |
| Q91106400 | Acute myeloid leukemia with isolated del(5q) is associated with IDH1/IDH2 mutations and better prognosis when compared to acute myeloid leukemia with complex karyotype including del(5q) |
| Q90854350 | Advances in patient care through increasingly individualized therapy |
| Q94484012 | Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells |
| Q100945788 | Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia |
| Q94484010 | Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia |
| Q60907779 | Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms |
| Q91974004 | Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients |
| Q90010398 | Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing |
| Q90442116 | Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis |
| Q107272881 | Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients |
| Q100463980 | FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome |
| Q90782147 | Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice |
| Q96430974 | Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia |
| Q91336418 | Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia |
| Q101122874 | Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia |
| Q96302419 | Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia |
| Q97549805 | KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia |
| Q96132188 | Landscape and function of multiple mutations within individual oncogenes |
| Q99370554 | Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation |
| Q103825970 | Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects |
| Q94600092 | MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia |
| Q91558662 | Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia |
| Q94588308 | Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia |
| Q101121278 | New strategies to treat AML: novel insights into AML survival pathways and combination therapies |
| Q96643266 | Novel treatment paradigms in acute myeloid leukemia |
| Q95334402 | RNA Splicing and Cancer |
| Q98386134 | RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses |
| Q92480642 | Rare germline variant contributions to myeloid malignancy susceptibility |
| Q91739677 | Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia |
| Q89866309 | Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia |
| Q98164451 | Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients |
| Q90589724 | Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation |
| Q91329861 | The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia |
| Q89582296 | The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling |
| Q89882194 | The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants |
| Q89723364 | Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin |
| Q98612249 | β-catenin and γ-catenin are dispensable for T lymphocytes and AML leukemic stem cells |
Search more.